Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients.

Sane RS, Steinmann GG, Huang Q, Li Y, Podila L, Mease K, Olson S, Taub ME, Stern JO, Nehmiz G, Böcher WO, Asselah T, Tweedie D.

J Pharmacol Exp Ther. 2014 Nov;351(2):403-12. doi: 10.1124/jpet.114.218081. Epub 2014 Sep 9.

PMID:
25204339
2.

Case study 3. Application of basic enzyme kinetics to metabolism studies: real-life examples.

Li Y, McCabe M, Podila L, Tracy TS, Tweedie DJ.

Methods Mol Biol. 2014;1113:441-60. doi: 10.1007/978-1-62703-758-7_20.

PMID:
24523124
3.

Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.

Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, Pak YA, Perloff ES, Reyner E, Balimane P, Brännström M, Chu X, Funk C, Guo A, Hanna I, Herédi-Szabó K, Hillgren K, Li L, Hollnack-Pusch E, Jamei M, Lin X, Mason AK, Neuhoff S, Patel A, Podila L, Plise E, Rajaraman G, Salphati L, Sands E, Taub ME, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yabut J, Yamagata T, Zhang L, Ellens H.

Drug Metab Dispos. 2013 Jul;41(7):1347-66. doi: 10.1124/dmd.112.050500. Epub 2013 Apr 25.

4.
5.

Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.

Taub ME, Podila L, Ely D, Almeida I.

Drug Metab Dispos. 2005 Nov;33(11):1679-87. Epub 2005 Aug 10.

PMID:
16093365

Supplemental Content

Loading ...
Support Center